20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T2635 | Org 27569 | Cannabinoid Receptor | |
Org 27569, an allosteric modulator of cannabinoid CB1 receptor, can induce a CB1 receptor state that is characterized by decreased inverse agonist affinity and enhanced agonist affinity. | |||
TN2268 | Tetrahydromagnolol | Cannabinoid Receptor , GPR , GABA Receptor | |
Tetrahydromagnolol can activate cannabinoid (CB) receptors. | |||
T2S0271 | Voacamine | Voacanginine | Cannabinoid Receptor , P-gp |
Voacamine (Voacanginine) is an indole alkaloid. Voacamine exhibits potent cannabinoid CB1 receptor antagonistic activity. Voacamine also inhibits P-glycoprotein (P-gp) action in multidrug-resistant tumor cells.Voacangini... | |||
T14011 | 2-Arachidonoylglycerol | Cannabinoid Receptor , Endogenous Metabolite | |
In the central nervous system, 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand | |||
T7375 | A-836339 | Cannabinoid Receptor | |
A-836339 acts as a potent cannabinoid receptor full agonist which has a higher affinity for the peripheral CB2 receptor (Ki = 0.64 nM) over the central CB1 receptor (Ki = 270 nM). It displays analgesic, anti-inflammatory... | |||
T7316 | LY2828360 | Cannabinoid Receptor | |
LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM). It selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively). | |||
T1915 | AM251 | Cannabinoid Receptor , GPR | |
AM251 is a effective CB1 receptor antagonist (IC50/Ki: 8 /7.49 nM) that displays 306-fold selectivity over CB2 receptors; also effective GPR55 agonist (EC50: 39 nM). | |||
T3699 | Bay 59-3074 | Cannabinoid Receptor | |
Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic and antiallodynic properties. | |||
T4453 | JD-5037 | JD 5037 | Cannabinoid Receptor |
JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM. | |||
T28468 | PSNCBAM-1 | PSNCBAM 1 | Cannabinoid Receptor |
PSNCBAM-1 (PSNCBAM 1) is a CB1 receptor negative allosteric modulator (EC50 = 0.1 μM) with hypophagic effects in vivo. PSNCBAM-1 can be used for obesity studies. | |||
TN1465 | Cannabigerol | NOS , 5-HT Receptor , ROS | |
Cannabigerol is a high affinity α±2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist ; also binds to the CB2 receptor; it can relieve interocular pressur... | |||
T10696 | CB2 modulator 1 | Cannabinoid Receptor | |
CB2 modulator 1 is a potent CB2 modulator. It can be used for the research for immune disorders, osteoporosis, inflammation, renal ischemia. | |||
T3530 | Otenabant | CP-945598 | Cannabinoid Receptor |
Otenabant (CP-945598) has been investigated for the treatment of Obesity. | |||
T1519L | Rimonabant | SR141716 | Cannabinoid Receptor , Antibacterial , Acyltransferase |
Rimonabant (SR141716) is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant... | |||
T13803 | N-Oleoyl glycine | Cannabinoid Receptor , Akt , Endogenous Metabolite , PPAR | |
N-Oleoyl Glycine, a Lipoamino Acid, Stimulates Adipogenesis Associated With Activation of CB1 Receptor and Akt Signaling Pathway in 3T3-L1 Adipocyte | |||
T8511 | TM38837 | Cannabinoid Receptor | |
TM38837 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes. | |||
T9466 | RTICBM-189 | Others | |
RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB1) receptor with a pIC50 of 7.54 in Ca2+ mobilization assay. RTICBM-189 has pIC50s of 5.29 and 6.25 for hCB1 and mCB1, respectivel... | |||
T8425 | Linoleoyl Ethanolamide | TRP/TRPV Channel | |
Linoleoyl Ethanolamide is an endocannabinoid agent. It acts by binding to TRPV1 increasing ERK phosphorylation and AP-1 dependent transcription in CB-receptor in an independent manner. | |||
T4654 | (±)-Ibipinabant | (±)-BMS6462,SLV319,(±)-SLV319 | Cannabinoid Receptor |
(±)-Ibipinabant ((±)-SLV319) has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes. | |||
T1519 | Rimonabant hydrochloride | SR 151716A,SR 141716A | Cannabinoid Receptor , Antibacterial |
Rimonabant hydrochloride (SR 141716A) is a cannabinoid receptor antagonist, binding selectively to central cannabinoid receptors (CB1) with high affinity. |